about
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal AntibodiesCollaborative approach to Optimise MEdication use for Older people in Nursing homes (COME-ON): study protocol of a cluster controlled trialDevelopment and validation of COMPASS: clinical evidence of orphan medicinal products - an assessment tool.Reimbursement of orphan drugs in Belgium: what (else) matters?Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the FutureAdoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi PanelThe Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial LandscapeCan authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory studyA review of the value of innovation in inhalers for COPD and asthma.Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers.Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FuturePayers' Views of the Changes Arising through the Possible Adoption of Adaptive PathwaysCost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.Off-label use of orphan medicinal products: a Belgian qualitative study.Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement.Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.Barriers to the uptake of biosimilars and possible solutions: a Belgian case study.Analysis of French generic medicines retail market: why the use of generic medicines is limited.The insights of health and welfare professionals on hurdles that impede economic evaluations of welfare interventions.Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability.Appropriateness of Acid Suppression Therapy.Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.Clinical, Economic and Policy Implications of Drug Shortages in the European Union.Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast CancerEthical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium.Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations.Policies for biosimilar uptake in Europe: An overview.The Evaluation of Economic Methods to Assess the Social Value of Medical Interventions for Ultra-Rare Disorders (URDS).Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders.Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries.Financial based agreements and performance based agreements: the Belgian experience.Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.Health-care use drives the economic burden of blood disorders in Europe.Market access of orphan drugs and the role of multi-criteria decision making.Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other IndustriesPatient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and PracticeBarriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
P50
Q26738325-53C9AA2C-1DA3-4502-A41F-5D15662F61B8Q28602757-BB3EADD5-1D19-47F9-B9A6-F6B355821841Q30559014-241D2856-36B1-4A86-901B-2AB0D37D81ABQ30587491-23F42A1E-D022-4A6B-872B-FB05D684D486Q30843820-9A128A0E-0AF7-4BF3-9A0E-217B3D5A9BEDQ33740641-26AE3984-FF2A-42B8-BE04-1F326044A9C3Q33774645-522F7B4F-C43D-4F09-9C8A-4D32088F9481Q33816182-89469D60-8CC7-44E1-B00A-788FFA2A73ABQ36325432-31553305-A490-49BA-9B70-1DC8F43F9053Q36714639-9A5286D6-1208-4981-B4F6-9DFFD3E78753Q36937790-B59FD97B-8B9F-4F5C-BACA-57ECF366259EQ37135584-C142F4EC-9523-4C50-9760-62C6A10C3321Q37290101-6DB66EA0-643A-4AAF-9F08-FB0B27C6E7F2Q37299398-1A4DE154-D66F-48F7-A958-51B56D099D9BQ37377924-6CCAE97B-2E3A-4DDB-B60E-732F30C7D08EQ37380325-0E6FB9DA-88B4-471F-AB30-4D48909A35B1Q37441285-37E75B28-54DD-47BB-8DC0-2A03C86B3A23Q38209872-7493FE17-266B-4254-BFD2-374676812473Q38237236-8D1C5BF3-A54C-4FCF-A2EA-BD00426A8A77Q39090440-A9C2877E-CDD6-4CFA-80B2-AA5CCFEEC211Q39205049-D5FF4135-AFD7-4B88-B9EC-2535687923C1Q39369057-362200D7-EEB7-4E39-9277-335F70A3E734Q39403982-9864DB30-D035-4ACC-9B92-ABADFA56516DQ39536773-DD5CE0F0-7E66-41A6-87D1-F795622DD7ABQ41526451-BFF39E84-3701-49AC-B9C6-3F1E4BB73828Q41684418-6E23CD71-FE11-4F74-97A2-79679C85DCDDQ44909469-5362B21D-8801-42B7-8DB6-8CA7CA5EB8D9Q45349937-B1D97478-E557-4EEE-BBD0-EDE9F7586F2FQ45871637-EFC2EB24-4622-4585-82D4-3C8453740D61Q47173303-CD462F56-030F-4B17-9810-664644550DA5Q47571356-545D6D36-19AA-4CA6-8E92-4C49B13EB059Q47571494-823E3147-93A3-42C2-AACC-8B6801687217Q48505941-6F3FA5FC-253F-46D8-A79F-C78BAC3F7DBCQ49162947-6FC4803F-1404-41E2-AD90-4B4974DE7EF1Q50953891-ADB6F791-5C36-4169-BAAD-1821FBDFC86FQ53748715-4420E748-3EB6-4447-B794-F9538574F5AAQ54988613-27B42CAE-265B-4F8C-AE95-02A64B815D65Q57486628-7E7B8C7D-2818-4E58-B4DD-E32F0C0F591DQ58572925-918BBB26-E2F3-420F-93BD-41EDD07504E7Q60046512-F42DB71E-58F1-407B-80DE-9608806343FA
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Steven Simoens
@en
Steven Simoens
@nl
type
label
Steven Simoens
@en
Steven Simoens
@nl
altLabel
S Simoens
@en
S. Simoens
@en
Simoens S
@en
Simoens S.
@en
Simoens
@en
prefLabel
Steven Simoens
@en
Steven Simoens
@nl
P31
P496
0000-0002-9512-2005